Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape
Vaccitech (UK) Limited
Fri, January 14, 2022, 8:34 AM·4 min read
Live webcast will be at 8:30 a.m. EST on January 25
OXFORD, United Kingdom, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced it will host a virtual Key Opinion Leader (“KOL”) event on VTP-300, in development as a key component of a functional cure therapy for chronic hepatitis B (CHB) infection, and the broader CHB therapeutics landscape. The event will be webcast live on January 25th at 8:30 a.m. EST.
Featured speakers:
Dr. Kaushik Agarwal, consultant hepatologist and transplant physician at the Institute of Liver Studies at King’s College Hospital, Viral Hepatitis Service lead, and Director of the NIHR South London Clinical Research Network.
Dr. Henry L. Y. Chan, head of the Division of Gastroenterology and Hepatology, Director of the Institute of Digestive Disease, the Center for Liver Health, and the Office of Global Engagement. Dr. Chan is also the Assistant Dean of External Affairs for the Faculty of Medicine at CUHK and the Course Director for the Master of Science in Gastroenterology at CUHK.
Vaccitech’s Virtual KOL Event details are as follows:
Tuesday, January 25th, 2022, 8:30 a.m. EST – 10:00 a.m. EST
A replay of the webcast will be available at the same location
About Vaccitech plc
Vaccitech (“the Company”) is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines for the treatment and prevention of infectious disease, cancer, and autoimmune disease. The company’s proprietary platforms comprise modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, the well-validated Modified Vaccinia Ankara, or MVA, all of which lack the ability to replicate in humans, and the SNAPvax™ and Syntholytic™ polymer-based platforms. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors, viral infections, autoimmunity, and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.作者: newchinabok 时间: 2022-1-14 19:45